Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Active Filter(s):
Details:
Under the termination, Acorda will regain global commercialization rights to Fampyra, a prolonged-release tablet formulation of the drug fampridine (4-aminopyridine, 4-AP or dalfampridine) for adult patients with multiple sclerosis with walking disability.
Lead Product(s): Fampridine
Therapeutic Area: Neurology Product Name: Fampyra
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: $510.0 million Upfront Cash: $110.0 million
Deal Type: Termination January 11, 2024
